Epia Neuro develops minimally invasive, closed‑loop neurotechnology that translates a patient’s neural intent into real‑time therapeutic action.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with neurological injuries such as stroke often retain the neural intent to move, but current neurostimulation therapies are static, require bulky chest generators, and need repeated surgeries to replace batteries, limiting long‑term effectiveness and accessibility.
Solution
Epia Neuro offers a minimally invasive, implantable neurotechnology that closes the loop between a patient’s neural intent and therapeutic action. The system continuously records intracranial signals and delivers adaptive stimulation in real time, eliminating the need for fixed‑parameter programming. Power is supplied wirelessly via a non‑invasive headset, removing the requirement for a chest‑mounted generator and avoiding battery‑replacement surgeries. The implant locks into a permanent cradle, allowing future hardware upgrades without additional invasive procedures. Designed for sub‑hour implantation, the platform aims to be scalable across neurology indications, with stroke therapy currently serving as the initial clinical validation.
Target Audience
Primary customers are neurosurgeons, neurologists, and rehabilitation centers seeking advanced, long‑term neuromodulation solutions for stroke and other neurological disorders.
Features
- Closed‑loop intelligence that adjusts stimulation parameters based on real‑time neural signal feedback
- Fully rechargeable architecture using a non‑invasive headset for daily charging
- Implantable design without a chest generator, reducing hardware bulk and infection risk
- Permanent cradle interface enabling hardware upgrades without further surgery
- Minimally invasive implantation technique comparable to sub‑hour procedures for broad clinical adoption
- Adaptive stimulation targeting both motor and cognitive deficits in stroke patients